ABL Bio Inc.

KOSDAQ 298380.KQ

ABL Bio Inc. EBITDA Margin for the year ending December 31, 2023: 3.21%

ABL Bio Inc. EBITDA Margin is 3.21% for the year ending December 31, 2023, a -68.51% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

ABL Bio Inc. EBITDA Margin for the year ending December 31, 2022 was 10.19%, a 101.31% change year over year.
ABL Bio Inc. EBITDA Margin for the year ending December 31, 2021 was -775.58%, a -17.56% change year over year.
ABL Bio Inc. EBITDA Margin for the year ending December 31, 2020 was -659.73%, a 25.32% change year over year.
ABL Bio Inc. EBITDA Margin for the year ending December 31, 2019 was -883.41%, a 90.41% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

KOSDAQ: 298380.KQ

ABL Bio Inc.

CEO	Dr. Sang Hoon Lee Ph.D.
IPO Date	Dec. 19, 2018
Location	South Korea
Headquarters	16 Daewangpangyo-Ro 712 Beon-Gil
Employees	102
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.

Key trends

Past 5 years